Loading patent…
AssigneeThe Penn State Research Foundation
InventorsAnthony Paul Schmitt, Phuong Tieu Schmitt, Greeshma Vivekananda Ray
Estimating the term…
Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.
A paramyxovirus virus like particle (VLP) comprising a contiguous recombinant polypeptide comprising i) from 10-120 amino acids of a C-terminal domain of a paramyxovirus nucleocapsid (N) protein, and ii) a polypeptide sequence of a single chain antibody or an antigen binding fragment thereof.
A method for introducing a polypeptide sequence into a cell comprising contacting the cell with a virus like particle (VLP) comprising a contiguous recombinant polypeptide comprising i) from 10-120 amino acids of a C-terminal domain of a paramyxovirus nucleocapsid (N) protein, and ii) a polypeptide sequence of a single chain antibody or an antigen binding fragment thereof such that the contiguous recombinant polypeptide comprising the C-terminal domain of the paramyxovirus nucleocapsid (N) protein and the a polypeptide sequence of the distinct protein enters the cell.
Dependencies are inferred from the claim text.